Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The players are vying in the CD19 x CD20 Car-T arena.
But the former is paying a fraction of what Merck shelled out for raludotatug.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
